Research goals: Metabolic & Weight Description Retatrutide (development code LY3437943) is a synthetic, once-weekly triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors that has been the subject of peer-reviewed phase 1 and phase 2 randomized controlled trials published in The New England Journal of Medicine , The Lancet , and Nature Medicine , including investigations of body weight, glycemic control, and hepatic steatosis in adult human participants
In medicine, it is used as a therapeutic agent to treat various diseases
doi: .10.1016/j.bbagen.2012.11.002 [PubMed: 23671931] [CrossRef] 129
Techniques such as erythrocyte hitchhiking, where nanoparticles temporarily attach to red cell membranes, enable targeted delivery to specific organs while reducing systemic toxicity (Zhang et al., 2022)
Measuring waist circumference weekly gives a more accurate picture of fat loss, especially in the first 8-12 weeks when water weight fluctuations can obscure true progress
doi:10.1161/CIRCRESAHA.117.309715 79
